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Research article
Factors associated with loss to clinic among HIV patients
not yet known to be eligible for antiretroviral therapy (ART)
in Mozambique
Rituparna Pati§,1,2, Maria Lahuerta3,4, Batya Elul3,4, Mie Okamura3, Maria Fernanda Alvim3, Bruce Schackman5,
Heejung Bang6, Rufino Fernandes3, Americo Assan7, Josue Lima3 and Denis Nash3,4,8 for the Identifying Optimal
Models of HIV Care in Mozambique Study Group
§Corresponding author: Rituparna Pati, Spencer Cox Center for Health, St. Luke’s and Roosevelt Hospitals, 390 West 114th Street, Scrymser Building, 1st Floor,
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Abstract
Introduction: Retention in HIV care prior to ART initiation is generally felt to be suboptimal, but has not been well-
characterized.
Methods: We examined data on 37,352 adult pre-ART patients (ART ineligible or unknown eligibility) who enrolled in care during
20052008 with 1 clinical visit at 23 clinics in Mozambique. We defined loss to clinic (LTC) as 12 months since the last visit
among those not known to have died/transferred. Cox proportional-hazards models were used to examine factors associated
with LTC, accounting for clustering within sites.
Results: Of 37,352 pre-ART patients, 61% had a CD4 count within three months of enrolment (median CD4: 452, IQR: 345611).
17,598 (47.1%) were ART ineligible and 19,754 (52.9%) were of unknown eligibility status at enrolment because of missing
information on CD4 count and/or WHO stage. Kaplan-Meier estimates for LTC at 12 months were 41% (95% CI: 40.241.8) and
48% (95% CI: 47.248.8), respectively. Factors associated with LTC among ART ineligible patients included male sex
(AHRmen_vs_non-pregnant women: 1.5; 95% CI: 1.41.6) and being pregnant at enrolment (AHRpregnant_vs_non-pregnant women: 1.3;
95% CI: 1.11.5). Older age, more education, higher weight and more advanced WHO stage at enrolment were independently
associated with lower risks of LTC. Similar findings were observed among patients whose ART eligibility status was unknown at
enrolment.
Conclusions: Substantial LTC occurred prior to ART initiation among patients not yet known to be eligible for ART, including
nearly half of patients without documented ART eligibility assessment. Interventions are needed to target pre-ART patients who
may be at higher risk for LTC, including pregnant women and patients with less advanced HIV disease.
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Introduction
While the rapid expansion of access to antiretroviral therapy
(ART) to nearly 4 million patients in sub-Saharan Africa has
been a major accomplishment of HIV care and treatment
programs [1], loss to clinic (LTC) of patients enrolled in HIV
care is a persistent challenge [2]. Prior studies attribute large
numbers of LTC of ART patients to early mortality [37], but
patients who are not yet eligible for ART are less likely to
have died [8]. However, they remain at risk of late ART
initiation [9,10] and, consequently, increased risk of early
mortality after starting ART [1116]. Furthermore, pre-ART
patients who are neither engaged in care nor on ART are
more likely to transmit HIV to sex partners than those who
engage in care and initiate early ART [17].
Growing recognition of the benefits of timely treatment
and the consequences of losing pre-ART eligible patients is
leading to increased awareness of the importance of regular
CD4 and clinical monitoring before treatment eligibility
[18,19]. The limited data available suggest that the losses
of pre-ART eligible patients are significant [8,12]. A systema-
tic literature review of patient retention in sub-Saharan
Africa estimated that fewer than one-third of patients remain
Meeting at which data was partially presented:
6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July 1720, 2011. Abstract reference number
A-361-0207-00823.
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continuously in care between testing HIV-positive and start-
ing ART; specifically, a median of 45% (range 558%) of
patients were lost to care after enrolment. However, the
quality and heterogeneity of the studies limit the interpreta-
tion of these results [20].
With 11.5% of adults 1549 years old living with HIV in
2009, Mozambique has one of the highest HIV seropreva-
lence rates in sub-Saharan Africa and has rapidly scaled up
HIV testing and ART availability in recent years [21]. We used
routine data from 23 clinics from the national program to
determine the proportion of ART-ineligible patients who
were LTC. We also examined LTC among patients without
documentation of ART eligibility because they make up a
substantial portion of the patient population and they may
have been deemed to be ART ineligible on initial clinical
assessment without confirmation by CD4 count or WHO
stage. We identified factors associated with LTC and des-
cribed outcomes for patients who were not LTC.
Methods
Ethics statement
The study utilized data that are routinely collected by sites
for service delivery and anonymized for analysis. This study
is part of the Identifying Optimal Models of HIV Care and
Treatment in Mozambique Collaboration, which was ap-
proved by the Mozambican National Ethics Committee, the
Columbia University Medical Center IRB, the US Centers for
Disease Control and Prevention, and PEPFAR’s Office of the
Global AIDS Coordinator.
Study design and study population
We used routinely collected service delivery data on HIV-
infected adult patients (]15 years old) enrolled at 23 free
HIV care and treatment clinics across Mozambique that were
part of the Mozambican National ART Program that were
receiving PEPFAR support via the ICAP-Columbia University.
We conducted a retrospective cohort study of adults enrolled
in care between January 2005 and December 2008. We
reviewed patient outcomes through December 2009, allow-
ing for at least one year of follow-up for all patients.
Patients were included in the study if they were not on
ART or not known to be eligible for ART at enrolment. ART
eligibility throughout the study period was defined as:
1) WHO stage IV disease, 2) WHO stage III and CD4 count
B350 cell/mL, or 3) CD4 count B200 cells/mL irrespective of
WHO stage. For baseline patient characteristics (i.e. weight,
CD4 count, WHO stage), we used any documented measure
obtained within three months of enrolment.
We divided the study population into two groups: 1) ART
ineligible and 2) ART eligibility unknown if either CD4
count or WHO stage were missing within three months of
enrolment. We analyzed data from patients who were ART
ineligible or eligibility was unknown and who returned for at
least one follow-up visit. We excluded those who presented
for only one visit because patients are not considered
enrolled into care until a physician has reviewed their file,
which often did not occur until a second follow-up visit. We
also excluded those who were known to have transferred
care to another facility and those who were documented as
dead after one visit.
Data and measures
National guidelines during the study period recommended
that HIV patients undergo a comprehensive medical history
assessment with a physical examination at their first clinic
visit. Due to high demands on CD4 machines and lack of
sample storage (cold chain) at many clinics, patients were
scheduled to return to clinic on a subsequent day to have a
CD4 count drawn to assess ART eligibility when specimens
could be processed on the same day. For patients not ART
eligible, the guidelines specified semi-annual visits with
clinical and CD4 count monitoring for ART eligibility.
Patient information collected during each visit was docu-
mented on national patient forms that were entered daily
by trained data clerks into a Microsoft Access electronic
database that was developed by ICAP-Mozambique and
deployed at all 23 sites. Each clinic contributed patient-level
data for the entire study period. Data quality assessments
(reviewing completeness and accuracy of the data) were
performed every six months, with feedback to clinic staff on
areas needing improvement.
LTC was defined as having occurred in a patient when 12
or more months elapsed since the last documented clinic
visit. Patients were censored from the analysis if they started
ART or met eligibility criteria for starting ART. Those known
to have died or transferred to another facility were also
censored.
The LTC event date for a lost patient was defined as 90
days after the last documented visit date. We calculated the
number of days in care before LTC (time to LTC) as the
difference between enrolment and the LTC event dates.
Statistical analysis
We compared characteristics of patients who were ART in-
eligible with those whose ART eligibility status was unknown
at enrolment, using the Chi-square test for categorical data
and student t-test for continuous variables. We used Kaplan-
Meier estimates to compute the proportion LTC at 6 and 12
months after enrolment. We used Cox proportional-hazards
models, accounting for clustering at site level, to identify
factors associated with LTC separately for the ART ineligible
and ART eligibility unknown populations in bivariate and
multivariate analyses.
Sex, age, marital status, number of children, socio-
economic status, education, weight, CD4 count and WHO
stage at enrolment were examined in the univariate models.
We created a scale of socio-economic status (zero to two
points), assigning one point each for having electricity and
refrigeration. Models were adjusted for year of enrolment;
missing data for each factor was modelled as a separate
category. All variables from the univariate models were
included in the final multivariable model. Associations were
examined at a pB0.05 significance level (2-sided test).
Multiple imputations with sensitivity analyses were con-
ducted to assess the potential impact of missing data.
Data were analyzed using SAS software 9.2 (SAS Institute,
Cary, NC).
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Results
Study population
Overall, 57,880 pre-ART patients not yet known to be
clinically eligible for ART enrolled in HIV care at 23 clinics
between January 1, 2005 and December 31, 2008. The
population was divided into ART ineligible (17,775; 30.7%)
and ART eligibility unknown (40,105; 69.3%). More than one-
third of the population (19,954) had no follow-up after the
first clinic visit and was excluded from further analysis.
The final study population was 37,352 pre-ART patients
(17,598 ART ineligible and 19,754 eligibility unknown). Table 1
shows that the study population was 70.7% women and
had a median age of 31.0 years. Approximately 8.5% of ART
ineligible women and 7.0% of women with unknown ART
eligibility were pregnant at enrolment. More than half of
ART ineligible patients (54%) were married or in union and
had completed primary school. Nearly three-quarters of the
study population was documented as living without electricity
or a freezer.
Between 2005 and 2006, the proportion of ART ineligible
patients that enrolled in care increased from 25.4% (1484
of the 5850) to 52.3% (4709 of 9000) of pre-ART patients
(ART ineligible or eligibility unknown); the proportion of ART
ineligible patient enrolment stabilized in 2007 and 2008 at
just over 50%. The enrolment of patients whose ART
eligibility status was unknown was 74.6% (4366) of pre-ART
patient enrolment in 2005 and 49.2% (5559) in 2008. The
largest proportion of patients was referred into care from
VCT; significant proportions were also referred from ‘‘other
testing facilities’’ and PMTCT. Of note, point of entry data was
missing for a high proportion of ART eligibility unknown
patients (along with marital status, education and weight).
Within three months of enrolment, 61% of pre-ART
patients had a CD4 count measurement with a median of
452 cells/mL (IQR: 345611 cells/mL). Of those who were
ART ineligible (N17,598), 12,992 (73.8%) remained ART
ineligible for the duration of follow-up (median follow-up
time213 days; IQR 113472 days). The remainder of the
ART ineligible patients either met criteria for ART eligibility
(4.6%) or started ART (21.6%).
Of those whose ART eligibility status was unknown at
enrolment (N19,754), 2756 (14.0%) were eventually
staged as ART ineligible and 1,169 (5.9%) were staged as
ART eligible but not started on ART at a median of 207 days
and 235 days after enrolment, respectively. An additional
4,711 (23.8%) were started on ART. The majority, 11,118
(56.3%), neither completed eligibility assessment nor started
ART at the clinic where they initially enrolled before the end
of observation in 2009.
Loss to clinic of ART ineligible patients and patients with
unknown ART eligibility
Nearly half of the study population (17,722; 47.4%) was
LTC during the observation period. Of the 12,992 patients
who remained ART ineligible, 7633 (58.8%) were LTC while
4,593 (35.4%) remained in care during the study period. On
average, patients who were ART ineligible at enrolment
had three clinic visits during the study follow-up period. The
Kaplan-Meier estimate of LTC at 12 months for ART ineligible
patients was 41% (95% CI: 40.241.8%) and those lost were
LTC at a median 137 days after enrolment. The median CD4
count last documented for LTC patients was 482 cells/mL
[IQR: 368648]. The distribution of last known WHO stages
among LTC patients was 47% stage I, 28% stage II and 25%
stage III.
Patients whose ART eligibility status was unknown at
enrolment and were LTC were lost at a median 124 days after
enrolment. Most of those who were LTC were lost after a
second clinic visit (81.6%). The Kaplan-Meier estimate of LTC
of patients whose ART eligibility status was unknown at
enrolment was 48% (95% CI: 47.248.8%) at 12 months after
enrolment. Of those who had a CD4 count before LTC
(24.1%), the median CD4 count was 447 cells/mL [IQR: 329
621]. The last documented WHO stages before LTC showed a
distribution of 34% stage I, 26% stage II and 40% stage III.
Among those patients who were known to be ART
ineligible at enrolment, the proportion of patients that
remained in care at the clinic through ART initiation during
the four years of observation was 21.6%; an additional 30.7%
were alive and in care at the clinic, but had not initiated ART
by the end of the study period. The median CD4 count at ART
initiation was 226 cells/mL (IQR: 176311). Of those whose
ART eligibility status was unknown at enrolment, 23.9%
eventually started ART, with a median CD4 count at ART
initiation of 196 cells/mL (IQR: 125277).
Factors associated with loss to clinic
Table 2 shows the results of crude and multivariable Cox
proportional hazards models with LTC as the outcome.
Among the ART ineligible patients, male sex was associated
with a significantly higher risk of LTC (adjusted hazards ratio
[AHR]men_vs_non-pregnant women: 1.48; 95% CI: 1.391.57).
Among women, being pregnant at enrolment was associated
with a higher risk of LTC (AHRpregnant_vs_non-pregnant women:
1.26; 95% CI: 1.081.46). Compared to the youngest age
group of 1525 year olds, older age was associated with a
lower likelihood of LTC (AHR: 0.55; 95% CI: 0.480.64 for
45 years). More education (AHRprimary_vs_none: 0.75; 95%
CI: 0.610.92) and higher weight (AHR56 kg_vs556 kg: 0.86;
95% CI: 0.800.93) were also associated with lower risks of
LTC. Compared to WHO stage I, more advanced stages of
clinical disease were associated with lower hazards of LTC
(AHR: 0.85; 95% CI: 0.770.95 for WHO stage II).
Similar findings were observed among patients whose ART
eligibility status was unknown at enrolment (Table 2). Male
sex was associated with a higher risk of LTC (AHRmen_vs_non-
pregnant women: 1.42; 95% CI: 1.331.51). Pregnancy was again
associated with a higher risk of LTC, though at a borderline
significant level (AHRpregnant_vs_non-pregnant women: 1.19; 95%
CI: 1.001.43). Older age, higher education levels and more
children were associated with lower risks of LTC. Higher
weight (AHR 56 kg_vs_556 kg: 0.81; 95% CI: 0.760.86) was
also associated with a significantly lower risk of LTC. Access
to both a freezer and electricity were associated with a
significantly lower risk of LTC (AHRboth_vs_none: 0.89; 95% CI:
0.820.98).
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Table 1. Baseline characteristics of pre-ART adults enrolled in care with at least one follow-up visit
Total Pre-ART ART ineligible ART eligibility unknown
N37,352 N17,598 N19,754
n Percentage n Percentage n Percentage
Sex
Male 10,946 29.3 5,084 28.9 5862 29.7
Female (not pregnant at enrolment) 23,526 63.0 11,013 62.6 12,513 63.3
Female (pregnant at enrolment) 2880 7.7 1501 8.5 1379 7.0
Age, mean in years (median, IQR) 33.3 31 (2540) 33.2 31 (2540) 33.4 31 (2540)
Age, intervals
1525 9806 26.3 4666 26.5 5140 26.0
2635 14,147 37.9 6659 37.8 7488 37.9
3645 8215 22.0 3873 22.0 4342 22.0
4655 3800 10.2 1761 10.0 2039 10.3
55 1384 3.7 639 3.6 745 3.8
Marital status
Married/in union 18,523 49.6 9550 54.3 8973 45.4
Single 11,143 29.8 5212 29.6 5931 30.0
Widowed 2544 6.8 1276 7.3 1268 6.4
Missing/other 5142 13.8 1560 8.9 3582 18.1
Number of children, mean (median, IQR) 2.1 2 (03) 2.3 2 (03) 2.0 1 (03)
n1 child 25,725 68.9 12,954 73.6 12,771 64.7
Education
None or did not finish primary school 2218 5.9 1286 7.3 932 4.7
Primary school 19,754 52.9 9495 54.0 10,250 51.9
Secondary school or higher 7631 20.4 4069 23.1 3562 18.0
Missing 7758 20.8 2748 15.6 5010 25.4
SES
Lower (no electricity) 27,889 74.7 12,157 69.1 15,732 79.6
Low (electricity only) 3598 9.6 2148 12.2 1450 7.3
Higher (electricity and freezer) 5861 15.7 3291 18.7 2570 13.0
Missing 4 0.0 2 0 2 
Year of enrolment
2005 5850 15.7 1484 8.4 4366 22.1
2006 9000 24.1 4709 26.8 4291 21.7
2007 11,213 30.0 5675 32.3 5538 28.0
2008 11,289 30.2 5730 32.6 5559 28.1
Point of entry
VCT 14,382 38.5 7897 44.9 6485 32.8
PMTCT 3115 8.3 1490 8.5 1625 8.2
TB/HIV 232 0.6 101 0.6 131 0.7
Inpatient 2184 5.9 1015 5.8 1169 5.9
Outpatient 3006 8.1 1721 9.8 1285 6.5
Other 2541 6.8 771 4.4 1770 9.0
Missing/unknown 4240 11.4 1132 6.4 3108 15.7
Referral from another testing facility 7652 20.5 3471 19.7 4181 21.2
Weight at enrolment (in Kg)*
Mean (median, IQR) 56.7 55.5 (5062) 57.4 56 (5063) 55.7 55 (4961)
Missing weight 11,532 30.9 2784 15.8 8748 44.3
WHO stage at enrolment*
Stage I 10,871 29.1 7636 43.4 3253 16.4
Stage II 7883 21.1 5232 29.7 2651 13.4
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CD4 counts at enrolment were not significantly associated
with LTC for either group of patients. Missing CD4 count at
enrolment was associated with a lower risk of LTC among
those for whom ART eligibility was unknown. Results of
multiple imputation of missing CD4 values were highly
consistent in terms of the direction and magnitude of
association; p-values in sensitivity analyses were not mean-
ingfully different from those presented in Table 2.
Subanalyses of pregnant women
There were 2880 women who were documented as being
pregnant that enrolled in pre-ART care between January
2005 and December 2008. Figure 1 shows that pregnant
women were more likely to be LTC than men and non-
pregnant women. Approximately 57% of all pre-ART preg-
nant women were LTC at a median of 120 days after
enrolment. On average, pregnant women were LTC sooner
than other women and men; LTC appears to peak in the peri-
partum period (n1442; median time of LTC: 42 weeks
since last menstrual period [LMP]; IQR: 3651 weeks since
LMP).
ART eligibility staging and loss to clinic by site
At any of the 23 sites, the proportion of pre-ART patients
whose ART eligibility was documented within three months
of enrolment ranged from 7.1 to 78.6%. The proportion of
pre-ART patients who were LTC during the study period
ranged from 29.5 to 73.7%. The number of pre-ART patients
who enrolled in HIV care between January 2005 and
December 2008 at each site (clinic patient load) did not
correlate with the proportion of patients assessed for ART
eligibility or the proportion LTC from each site.
Discussion
Our results document the high magnitude of LTC prior to ART
eligibility and initiation across several sites and settings in
Mozambique, with a 12-month LTC proportion of 4148%
among those with 1 clinical care visit. The proportion of
37,352 patients who were not yet known to be eligible for
ART at enrolment and continued in care until ART initiation
during the study period is 23%, with an additional 25%
remaining in care at the site where they initially enrolled until
the end of follow-up. The large portion of patients who were
lost after just one clinic visit (19,783, or 34.5% of 57,880 pre-
ART patients) further magnifies the problem of pre-ART
attrition. These findings are relatively consistent with a
recent systematic literature review that estimated fewer
than one third of ART ineligible patients remain in contin-
uous care until ART initiation [20].
This study adds to the evidence that expansion of HIV
testing and counselling does not necessarily translate into
timely care engagement and CD4 testing [9,2224]. Our
study showed that 39% of patients not yet known to be ART
eligible did not have a documented CD4 count within three
months of their first visit. Providers’ perceptions of these
patients as healthy as well as the lack of access to immediate
CD4 testing may have led them to consider these patients
as ART ineligible without checking CD4 counts or formally
documenting disease stage, despite recommendations to do
both.
The use of point-of-care CD4 count technology at the
first visit may be one strategy for more rapid eligibility
assessment [25] and may help reduce the substantial loss of
patients we have seen after the first clinic visit. The
opportunity for patients to provide a sample and receive a
test result at the first visit might engage them in care by
raising their HIV-related health literacy and awareness before
logistical barriers such as lack of transportation, absence
from work and fear of stigma compete with their need and
desire to receive ongoing care [2630]. Researchers should
continue to evaluate point-of-care testing as a strategy to
improve patient retention in pre-ART care [3134].
Table 1 (Continued )
Total Pre-ART ART ineligible ART eligibility unknown
N37,352 N17,598 N19,754
n Percentage n Percentage n Percentage
Stage III 9495 25.4 4730 26.9 4765 24.1
Stage IV * * * * * *
Missing baseline WHO stage 9,103 24.4 * * 9103 46.1
CD4 count at enrolment*
5200 * * * * * *
200 and5275 2852 7.6 1943 11.0 909 4.6
275 and5350 3090 8.3 2150 12.2 940 4.8
350 and5500 7633 20.4 6146 34.9 1487 7.5
500 9248 24.8 7359 41.8 1889 9.6
Missing baseline CD4 count 14,529 38.9 * * 14,529 73.6
Mean (median, IQR) 502.7 452 (345611) 510.4 461 (357619) 476.9 422 (306588)
*Documented within three months of first clinic visit. The ART ineligible and ART eligibility unknown populations are significantly different
(pB0.0001) for all characteristics except median age (p0.05) and age intervals (p0.68).
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Table 2. Multivariable analysis of factors associated with LTC for ART ineligible population
ART ineligible (N17,598) ART eligibility unknown (N19,754)
Variable* Crude HR 95% CI AHR 95% CI Crude HR 95% CI AHR 95% CI
Sex
Non-pregnant female 1 1 1 1
Male (male vs. non-pregnant female) 1.25 1.171.33 1.48 1.391.57 1.24 1.181.30 1.42 1.331.51
Pregnancy (pregnant vs. non-pregnant
female)
1.58 1.351.84 1.26 1.081.46 1.56 1.222.00 1.19 1.001.43
Age
1525 1 1 1 1
2635 0.73 0.670.79 0.75 0.690.82 0.74 0.640.84 0.79 0.720.86
3645 0.58 0.520.65 0.60 0.550.67 0.66 0.570.75 0.73 0.690.79
45 0.57 0.490.65 0.55 0.480.64 0.61 0.510.72 0.65 0.590.72
Marital status
Married/in union 1 1 1 1
Single 1.02 0.941.11 1.00 0.921.10 1.02 0.931.11 1.00 0.911.11
Widowed 0.76 0.620.94 0.93 0.781.11 0.76 0.600.96 0.90 0.761.08
Missing/other 1.10 0.921.31 0.99 0.781.26 1.06 0.851.31 1.16 0.861.56
Number of children
0 1 1 1 1
1 0.94 0.871.03 0.99 0.911.08 0.94 0.801.10 0.94 0.791.02
2 0.82 0.740.90 0.91 0.821.02 0.87 0.751.00 0.87 0.760.99
3 or more 0.74 0.650.83 0.93 0.811.06 0.74 0.640.86 0.74 0.670.91
Education
None or did not finish primary school 1 1 1 1
Primary school 0.84 0.671.05 0.75 0.610.92 0.80 0.700.91 0.78 0.690.89
Secondary school or higher 0.78 0.611.00 0.66 0.530.81 0.66 0.580.74 0.60 0.530.67
Missing 0.96 0.721.29 0.91 0.691.21 0.72 0.550.95 0.80 0.641.00
SES
Lower (no electricity) 1 1 1 1
Low (electricity only) 0.94 0.821.08 0.98 0.861.11 1.12 0.961.30 1.10 0.991.21
Higher (electricity and freezer) 0.81 0.710.92 0.90 0.801.03 0.78 0.640.96 0.89 0.820.98
Weight at enrolment (in kg)**
Bor56kg 1 1 1 1
56 kg 0.85 0.770.93 0.86 0.800.93 0.84 0.770.91 0.81 0.760.86
Missing weight 0.84 0.591.20 0.95 0.701.29 0.76 0.501.17 0.84 0.701.01
WHO stage at enrolment***
Stage I 1 1 1 1
Stage II 0.81 0.730.89 0.85 0.770.95 0.92 0.801.05 0.93 0.851.01
Stage III 0.85 0.760.97 0.87 0.770.99 0.85 0.760.96 0.94 0.811.10
Stage IV * * * * * * * *
Missing baseline WHO stage * * * * 1.12 0.632.01 1.00 0.771.31
CD4 count at enrolment***
200 and5275 1 1 1 1
275 and5350 0.98 0.901.07 0.97 0.891.06 0.96 0.831.11 0.95 0.821.11
350 and5500 0.97 0.891.05 0.95 0.871.03 0.98 0.871.11 0.96 0.841.09
500 1.12 1.011.25 1.07 0.971.18 1.10 0.921.32 1.04 0.881.23
Missing baseline CD4 count * * * * 0.65 0.371.14 0.60 0.470.78
*Multivariable model was adjusted for year of enrolment.
**Median of 55 kg used for ART eligibility unknown population; weight documented within three months of first clinic visit.
***Documented within three months of first clinic visit.
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Nevertheless, the substantial loss of patients even after
ART eligibility assessment suggests that more than CD4
testing and clinical staging is necessary to retain ART
ineligible patients in care. Current guidelines do not offer
therapeutic interventions to asymptomatic patients with high
CD4 counts (i.e. 350 cells/mL), leaving patients without
concrete reasons such as medications to return for visits.
One recent study showed higher retention among pre-ART
patients who received prophylaxis for opportunistic infec-
tions (OI), such as cotrimoxazole or isoniazid, compared with
those who did not [35]. Although this strategy presents risks
of medication side effects, expanding cotrimoxazole eligibility
to all pre-ART patients may improve pre-ART retention rates,
and requires more investigation. We were unable to assess
the role of OI prophylaxis in our study due to incomplete
data. As HIV treatment guidelines expand and support grows
for the ‘‘test and treat strategy’’ [36], expanded or a universal
offering of ART may be implemented in the future, but
prevention of LTC requires more immediate and sustainable
interventions.
With women of reproductive age representing a growing
percentage of people enrolling in HIV care in Mozambique
[37], the higher risk of LTC observed among pregnant women
is particularly concerning. PMTCT programs refer pregnant
women into HIV care, but more support is needed to link,
engage and retain pregnant women once they enroll in care,
especially pregnant women in pre-ART care, as they need to
initiate and maintain treatment with ARVs both for their own
health and to prevent vertical transmission. Our study
showed that LTC among women who were pregnant at
enrolment peaked in the peri-partum period, perhaps as a
consequence of increased domestic demands in caring for
the newborn. Other studies also show poor retention of peri-
partum women, including one study of women who started
ART while pregnant and found higher rates of non-adherence
to ART after delivery [38]. Anticipating the needs of pregnant
women and providing them with outreach care and support
may be an effective means of keeping them engaged in care,
especially during the vulnerable peri-partum period [39].
This study is responsive to the urgent call for researchers
to closely examine the problem of LTC amongst patients not
yet eligible for ART [8,20,30,40]. While others have studied
isolated phases of pre-ART care [8,26,30,4143], this study
fills an important gap in the literature by documenting the
proportion of patients who enrolled in care before ART
eligibility and remained in care at until treatment initiation.
Furthermore, our data suggest that patients who enrol and
remain in care prior to ART eligibility eventually start ART at
median CD4 counts more in line with recommendations by
national guidelines, as compared with the majority of ART
patients that report medians much lower than the threshold
of 200 cells/mL [4,9]. This suggests that it is possible at least
for some patients to remain relatively continuously in pre-
ART care over longer periods such that appropriate monitor-
ing can occur, with treatment initiated in a relatively timely
fashion.
Our study has several findings and associated limitations
related to missing data. Poor documentation, incomplete
data entry, limited access to CD4 measurement or a com-
bination of these factors are likely reasons for substantial
missing information on ART eligibility at enrolment and soon
thereafter. The substantial portion of patients missing
information on ART eligibility criteria suggests that problems
in patient monitoring and data tracking are system-wide and
are adversely affecting rates of LTC. However, we could also
not quantify the extent to which information may have been
missing as a result of patients becoming LTC.
We could not report outcomes for those who are LTC,
including whether patients lost to clinic are in fact lost to
or disengaged from HIV care altogether; undocumented
transfers may account for a large proportion of patients
LTC, especially in the context of rapid scale-up and decen-
tralization of HIV programs during the study period. Similarly,
the proportion of lost patients who died is unknown but
likely small for ART ineligible patients, although high rates of
maternal mortality in Saharan Africa, where 1 in 31 women
die during childbirth (ranging from 470 to 930 deaths per
100,000 live births), may contribute [44], especially among
those LTC during the peri-partum period. As a result, the
proportion of patients who actually disengaged from HIV care
is most likely less than the proportion our study reports as
LTC. Research is needed to characterize the outcomes among
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Figure 1. LTC of ART ineligible patients and patients with unknown ART eligibility 12 months after enrolment.
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these patients, as well as the reasons for dropping out of
care, as has been done for ART patients [2,45].
Our findings on pregnant pre-ART women have important
implications for program implementers, but they should be
interpreted with caution. Pregnancy status and gestational
age were derived from patients’ verbal reports or documents
from other clinical services and were not verified by staff
entering the data. It is unclear howmanywomen weremissing
pregnancy status because they were never asked or the infor-
mation was never documented or entered; further, only half of
the women documented as pregnant also had documented
gestational age at enrolment. Finally, we studied pregnancy
only at enrolment and could not assess whether becoming
pregnant after enrolment is also a risk factor for LTC, which
would further raise our concern that pregnancy may be an
especially vulnerable period that should be the focus of
targeted interventions.
Conclusions
LTC among patients not yet eligible for ART or for whom ART
eligibility has not been assessed or documented is a major
barrier with the potential to undermine the success of HIV
care and treatment programs in sub-Saharan Africa. While
LTC of ART ineligible patients does not usually portend
immediate death, it perpetuates the pattern of late ART
initiation [9,10,46] and contributes to the high mortality
observed during the first year on ART. Furthermore, losing
patients who present for care is a missed opportunity to
prevent onward HIV transmission. Where resources allow, we
must better understand how to target and intervene with
patients prior to ART eligibility, especially men, pregnant
women and others who are at higher risk of LTC. Improved
patient tracking systems and more research on predictors
and outcomes for pre-ART patients will help shape the
development of effective interventions and programmatic
activities, especially as ART eligibility criteria are expanding or
are slated for expansion in many resource-limited settings.
Future studies should investigate reasons for missing ART
eligibility monitoring data, ascertain outcomes among those
LTC, and test interventions to retain pre-ART patients.
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